Previous Close | 8.20 |
Open | 8.29 |
Bid | 7.79 x 2200 |
Ask | 7.80 x 800 |
Day's Range | 7.74 - 8.38 |
52 Week Range | 3.32 - 9.38 |
Volume | 1,180,348 |
Avg. Volume | 1,337,818 |
Market Cap | 773.094M |
Beta (3Y Monthly) | 2.52 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -2.22 |
Earnings Date | Nov 12, 2019 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 20.80 |
Q3 2019 TG Therapeutics Inc Earnings Call
NEW YORK, Nov. 18, 2019 -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that Michael S. Weiss, the Company’s Executive Chairman and Chief Executive Officer, will.
NEW YORK, Nov. 12, 2019 -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced its financial results for the third quarter ended September 30, 2019 and recent company.
NEW YORK, Nov. 08, 2019 -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that a conference call will be held, Tuesday, November 12, 2019 at 8:30 AM ET to discuss.
100% overall response rate (ORR) in relapsed/refractory CLL patients (n=9) treated with U2 (umbralisib + ublituximab) plus venetoclax, with all patients at 12 months achieving.
Amid an overall bull market, many stocks that smart money investors were collectively bullish on surged through October 17th. Among them, Facebook and Microsoft ranked among the top 3 picks and these stocks gained 45% and 39% respectively. Our research shows that most of the stocks that smart money likes historically generate strong risk-adjusted returns. […]
The biotech sector has not been nearly as strong and is still off around 10% from the highs hit earlier in the year, as seen in the SPDR S&P Biotech ETF . TG Therapeutics should file another NDA for the treatment of Chronic Lymphocytic Leukemia, or CLL, in combination with its other late-stage compound TG-1101 sometime in the first half of 2020.
NEW YORK, Oct. 28, 2019 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (TGTX), a biopharmaceutical company developing medicines for patients with B-cell mediated diseases, today announced that the follicular lymphoma (FL) cohort of the UNITY-NHL Phase 2b pivotal trial evaluating single agent umbralisib, the Company’s novel, once daily, PI3K delta inhibitor, met the primary endpoint of overall response rate (ORR) as determined by Independent Review Committee (IRC) for all treated patients (n=118) who have received at least two prior lines of therapy including an anti-CD20 monoclonal antibody and an alkylating agent. The results met the Company’s prespecified ORR target of 40-50%.
TG Therapeutics, Inc. (TGTX) today announced that final long-term results from the Phase 3 GENUINE study demonstrated that ublituximab in combination with ibrutinib improved progression-free survival (PFS), as determined by Independent Review Committee (IRC). The GENUINE Phase 3 study evaluated ublituximab, the Company’s novel, glycoengineered anti-CD20 monoclonal antibody, in combination with ibrutinib, compared to ibrutinib monotherapy in patients with relapsed/refractory high-risk chronic lymphocytic leukemia (CLL).
In this article we are going to estimate the intrinsic value of TG Therapeutics, Inc. (NASDAQ:TGTX) by taking the...
NEW YORK, Oct. 02, 2019 -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that Michael S. Weiss, the Company’s Executive Chairman and Chief Executive Officer, will.
TG Therapeutics, Inc. (TGTX) today announced the publication of results from the multicenter first-in-human Phase I/Ib combination trial of ublituximab, the Company’s anti-CD20 monoclonal antibody, and umbralisib, the Company’s oral once-daily PI3K delta inhibitor in Blood, the Journal of the American Society of Hematology. Dr. Matthew Lunning, of the Fred and Pamela Buffett Cancer Center at the University of Nebraska Medical Center and lead enroller on this trial stated, “I have been involved in the development of umbralisib and ublituximab since 2014, and at our institution we have treated over 60 patients on clinical trials with umbralisib and ublituximab (U2) and/or in combination with other agents.
TG Therapeutics, Inc. (TGTX), today announced that data from two Phase 1/2 trials were presented at the XVIII International Workshop on Chronic Lymphocytic Leukemia (iwCLL), currently being held in Edinburgh, Scotland.
NEW YORK, Sept. 20, 2019 -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that Michael S. Weiss, the Company’s Executive Chairman and Chief Executive Officer, will.
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' It's only natural to consider a company's...
The following is a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs Sept. 11.) Avedro Inc (NASDAQ: AVDR ) Catalyst Pharmaceuticals ...
TG Therapeutics, Inc. (TGTX), today presented the first look at the ULTIMATE I & II Phase 3 trial design and demographic data and updated Phase 2 extension trial data for ublituximab, the Company’s novel, glycoengineered anti-CD20 monoclonal antibody, in relapsing forms of multiple sclerosis (RMS) at the 35th Annual Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), being held in Stockholm, Sweden. Michael S. Weiss, the Company’s Executive Chairman and Chief Executive Officer stated, “We are pleased to present the first look at the study design and patient demographics data from our Phase 3 ULTIMATE program.
TG Therapeutics, Inc. (TGTX), today announced that abstracts featuring ublituximab, the Company’s novel, glycoengineered anti-CD20 monoclonal antibody, in relapsing forms of multiple sclerosis (RMS) have been accepted for presentation at the upcoming 35th Annual Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), to be held September 11 – 13, 2019 in Stockholm, Sweden. Abstracts are now available online and can be accessed on the ECTRIMS meeting website at www.ectrims-congress.eu.
NEW YORK, Aug. 26, 2019 -- TG Therapeutics, Inc. (NASDAQ: TGTX) announced with great sadness the passing of longtime Board Member, Mark Schoenebaum, MD. "Everyone at TG is.
Q2 2019 TG Therapeutics Inc Earnings Call
On Monday morning, Benzinga Pro subscribers received an option alert due to an unusually large TG Therapeutics trade. Due to the relatively complex nature of the options market, options traders are generally considered to be more sophisticated than the average stock trader. In addition, large options traders are often professional, wealthy individuals or institutions, either of which could have unique insight or information about a company.
A look at the shareholders of TG Therapeutics, Inc. (NASDAQ:TGTX) can tell us which group is most powerful. Generally...
TGTX earnings call for the period ending June 30, 2019.
NEW YORK, Aug. 09, 2019 -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced its financial results for the second quarter ended June 30, 2019 and recent company.
NEW YORK, Aug. 07, 2019 -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that a conference call will be held, Friday, August 9, 2019 at 8:30 AM ET to discuss results.